로딩 중…
StockDiggingStockDigging

Biodyne Co., Ltd.

314930· KOSDAQ
₩9,970-7.77%
2026-06-19

Price Chart

Biodyne Co., Ltd.-39.58%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap296.75B KRW
Revenue6.98B KRW
Net Income1.97B KRW
Total Assets44.77B KRW
Net Assets44.30B KRW
Employees19
Value
P/E150.80x
P/B6.70x
PEG0.73x
P/S42.53x
EV/EBITDA146.01x
FCF Yield-0.88%
Profitability
ROE4.44%
ROA4.40%
Op. Margin27.93%
Revenue Growth-5.40%
Earnings Growth207.98%
Financial Health
Debt Ratio101.06%
Total Debt0 KRW
FCF-2.60B KRW
Cash12.22B KRW
Current Ratio39.77x
Net Debt/EBITDA-6.27x
Performance
1Y Return-39.58%
1M Return3.21%
From 52W High-42.27%
1Y MDD-42.91%
Trading
Volume65,059 shares
Foreign Own.4.21%
Per Share
EPS49 KRW
BPS1,503 KRW

Company Info

CEO 임욱빈
Employees 19
Founded 1999
HQ 서울특별시 성동구, KR

Established in 2013, the company develops, manufactures, and sells liquid-based cytology equipment and cancer diagnostic reagent kits, completing a special listing on the KOSDAQ market in 2021. It exports its independently developed blowing technology-based LBC equipment, 'PATHPLORER', and reagent kits to 13 countries, securing patents in multiple nations. The company has an exclusive license agreement with Roche for slide smearing device development, planning to unveil 'VENTANA SP400' in Japan in 2025 and pursue global sales. Biodine is headquartered in Seongdong-gu, Seoul.